These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26067141)

  • 1. Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome.
    Nguyen TT; Frater JL; Klein J; Chen L; Bartlett NL; Foyil KV; Kreisel FH
    Appl Immunohistochem Mol Morphol; 2016 Jul; 24(6):383-91. PubMed ID: 26067141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.
    Muenst S; Hoeller S; Dirnhofer S; Tzankov A
    Hum Pathol; 2009 Dec; 40(12):1715-22. PubMed ID: 19695683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma.
    Herbeck R; Teodorescu Brînzeu D; Giubelan M; Lazăr E; Dema A; Ioniţă H
    Rom J Morphol Embryol; 2011; 52(1):69-74. PubMed ID: 21424034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.
    O'Malley DP; Dogan A; Fedoriw Y; Medeiros LJ; Ok CY; Salama ME
    Ann Diagn Pathol; 2019 Apr; 39():105-110. PubMed ID: 30802809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TiA1 in advanced-stage classical Hodgkin's lymphoma: no prognostic impact for positive tumour cells or number of cytotoxic cells.
    Camilleri-Broët S; Fermé C; Berger F; Lepage E; Bain S; Brière J; Marmey B; Gaulard P; Audouin J
    Virchows Arch; 2004 Oct; 445(4):344-6. PubMed ID: 15221373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis.
    Hsi ED; Sup SJ; Alemany C; Tso E; Skacel M; Elson P; Alonso MA; Pohlman B
    Am J Clin Pathol; 2006 May; 125(5):776-82. PubMed ID: 16707382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact.
    Barros MH; Hassan R; Niedobitek G
    Clin Cancer Res; 2012 Jul; 18(14):3762-71. PubMed ID: 22645050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases.
    Tzankov A; Krugmann J; Fend F; Fischhofer M; Greil R; Dirnhofer S
    Clin Cancer Res; 2003 Apr; 9(4):1381-6. PubMed ID: 12684408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
    Karube K; Niino D; Kimura Y; Ohshima K
    Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma.
    Deau B; Bachy E; Ribrag V; Delarue R; Rubio MT; Bosq J; Varet B; Brousse N; Hermine O; Canioni D
    Leuk Lymphoma; 2013 Jan; 54(1):41-5. PubMed ID: 22667341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
    Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
    Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome.
    Andersen MD; Kamper P; Nielsen PS; Bendix K; Riber-Hansen R; Steiniche T; Hamilton-Dutoit S; Clausen M; d'Amore F
    Eur J Haematol; 2016 Mar; 96(3):252-9. PubMed ID: 25963595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
    Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB
    J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
    Rodig SJ; Ouyang J; Juszczynski P; Currie T; Law K; Neuberg DS; Rabinovich GA; Shipp MA; Kutok JL
    Clin Cancer Res; 2008 Jun; 14(11):3338-44. PubMed ID: 18519761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction.
    Tudor CS; Distel LV; Eckhardt J; Hartmann A; Niedobitek G; Buettner M
    Hum Pathol; 2013 Nov; 44(11):2475-86. PubMed ID: 24029709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood CD4/CD19 cell ratio is an independent prognostic factor in classical Hodgkin lymphoma.
    Gaudio F; Perrone T; Mestice A; Curci P; Giordano A; Delia M; Pastore D; Specchia G
    Leuk Lymphoma; 2014 Jul; 55(7):1596-601. PubMed ID: 24164533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma.
    Hasselblom S; Sigurdadottir M; Hansson U; Nilsson-Ehle H; Ridell B; Andersson PO
    Br J Haematol; 2007 May; 137(4):364-73. PubMed ID: 17456059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: Implications for immune dysregulation, prognosis and potential therapeutic targeting.
    Quesada AE; Assylbekova B; Jabcuga CE; Zhang R; Covinsky M; Rios A; Nguyen ND; Brown RE
    Int J Clin Exp Pathol; 2015; 8(10):13241-8. PubMed ID: 26722524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma.
    Klein JL; Nguyen TT; Bien-Willner GA; Chen L; Foyil KV; Bartlett NL; Duncavage EJ; Hassan A; Frater JL; Kreisel F
    Am J Clin Pathol; 2014 Mar; 141(3):381-7. PubMed ID: 24515766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma.
    Khan MR; Ahmad A; Kayani N; Minhas K
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3463-3466. PubMed ID: 30583670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.